The role of antileukotrienes in the treatment of asthma (Q28185790)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11426914 AND SRC:MED&resulttype=core&format=json

8 November 2019

review article

1 reference

title

The role of antileukotrienes in the treatment of asthma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11426914 AND SRC:MED&resulttype=core&format=json

8 November 2019

0 references

P E Korenblat

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11426914 AND SRC:MED&resulttype=core&format=json

8 November 2019

Antileukotriene Working Group

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11426914 AND SRC:MED&resulttype=core&format=json

8 November 2019

language of work or name

English

0 references

publication date

1 June 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11426914 AND SRC:MED&resulttype=core&format=json

Annals of Allergy, Asthma & Immunology

8 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11426914 AND SRC:MED&resulttype=core&format=json

8 November 2019

volume

86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11426914 AND SRC:MED&resulttype=core&format=json

8 November 2019

issue

6 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11426914 AND SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

31-39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11426914 AND SRC:MED&resulttype=core&format=json

Cellular events in the bronchi in mild asthma and after bronchial provocation

8 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Management of asthma with zafirlukast. Clinical experience and tolerability profile

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs.

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Antileukotriene drugs in the management of asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Zafirlukast: The First Leukotreene-Receptor Antagonist Approved for the Treatment of Asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

1 reference

7 January 2021

Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

1 reference

7 January 2021

A Risk-Benefit Assessment of Antileukotrienes in Asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Benefits from Adding the 5-Lipoxygenase Inhibitor Zileuton to Conventional Therapy in Aspirin-intolerant Asthmatics

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Worldwide clinical experience with the first marketed leukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Results of the First U.S. Double-Blind, Placebo-Controlled, Multicenter Clinical Study in Asthma with Pranlukast, a Novel Leukotriene Receptor Antagonist

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Effect of Pranlukast, a Leukotriene Receptor Antagonist, in Patients with Severe Asthma Refractory to Corticosteroids

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Therapeutic Effect of Pranlukast, a Selective Cysteinyl Leukotriene Receptor Antagonist, on Bronchial Asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Treatment of asthma with drugs modifying the leukotriene pathway.

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Challenge studies of a leukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Leukotriene antagonism in asthma and rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Reduced Allergen-Induced Nasal Congestion and Leukotriene Synthesis with an Orally Active 5-Lipoxygenase Inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Leukotriene-receptor antagonists

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Pulmonary Infiltrates, Eosinophilia, and Cardiomyopathy Following Corticosteroid Withdrawal in Patients With Asthma Receiving Zafirlukast

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Churg-Strauss Syndrome Associated With Zafirlukast

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Pulmonary eosinophilia associated with montelukast

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Formes Frustes of Churg-Strauss Syndrome

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Steroids and Churg-Strauss syndrome

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

Antileukotrienes in chronic urticaria

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)62309-5

7 January 2021

10.1016/S1081-1206(10)62309-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11426914 AND SRC:MED&resulttype=core&format=json

8 November 2019

1 reference